Recent Posts in September, 2010

• More Trouble for DePuy

  Sep 27, 2010
  A warning letter issued by the FDA on August 19, 2010 to DePuy Orthopaedics cites numerous cases where DePuy marketed two hip replacement systems ...
  Posted By Rheingold, Giuffra, Ruffo & Plotkin LLP
  Continue Reading

• Antipsychotics Linked to Thromboembolisms

  Sep 22, 2010
  New research published in the British Medical Journal suggests that atypical antipsychotics such as Seroquel, Mellaril and Clorazil could be the cause ...
  Posted By Rheingold, Giuffra, Ruffo & Plotkin LLP
  Continue Reading

• Congress to Hold Another J&J Recall Hearing, World Chair Resigns

  Sep 17, 2010
  The House Committee on Government Oversight and Reform is holding another hearing September 30th to question Johnson & Johnson executives about the ...
  Posted By Rheingold, Giuffra, Ruffo & Plotkin LLP
  Continue Reading

• Expert Panel links Biphosphonates to Femur Fracture, Wants New Labels

  Sep 14, 2010
  A task force convened by the American Society of Bone and Mineral Research has concluded that there is a connection between atypical femur fractures ...
  Posted By Rheingold, Giuffra, Ruffo & Plotkin LLP
  Continue Reading

• Conflicts of Interest Among Doctors and Device Makers

  Sep 13, 2010
  Less than half of surgeons who recieved $1 million or more in payments from medical device manufacturers disclosed their relationships when publishing ...
  Posted By Rheingold, Giuffra, Ruffo & Plotkin LLP
  Continue Reading

• Big Pharma and Ghostwriting

  Sep 8, 2010
  The practice of phamaceutical companies ghostwriting articles about their drugs has been questioned by doctors and patients for many years. A recent ...
  Posted By Rheingold, Giuffra, Ruffo & Plotkin LLP
  Continue Reading

• Saying "I'm Sorry" Really Does Help

  Sep 7, 2010
  There has been much media attention paid to doctors' reluctance to admit their mistakes and apologize. While there may be many reasons for such ...
  Posted By Rheingold, Valet, Rheingold, Ruffo & Giuffra LLP
  Continue Reading

• Allergan Settles DOJ Botox Probe for $600 million

  Sep 1, 2010
  Allergan has plead guilty to one misdemeanor in connection with off-label marketing of Botox and agreed to pay $600 million in fines, civil penalties, ...
  Posted By Rheingold, Giuffra, Ruffo & Plotkin LLP
  Continue Reading